Damora Therapeutics (DMRA) Free Cash Flow (2019 - 2026)
Damora Therapeutics' (DMRA) quarterly Free Cash Flow came in at -$20.6 million in Q1 2026, down 695.29% YoY from $3.5 million in Q1 2025, and down 1533.4% on a QoQ basis from $1.4 million in Q4 2025.
Damora Therapeutics (DMRA) Free Cash Flow (2019 - 2026) Analysis & Trends
Damora Therapeutics (DMRA) has 8 years of Free Cash Flow data on file, last reported at -$20.6 million in Q1 2026.
- Quarterly Free Cash Flow fell 695.29% year-over-year to -$20.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$24.5 million (down 78.64% YoY) and the FY2025 annual result came in at -$6.5 million, up 62.94% from the prior year.
- Free Cash Flow declined to -$20.6 million in Q1 2026, from $1.4 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $1.4 million in Q4 2025 to a low of -$20.6 million in Q1 2026.
- A 5-year average of -$7.3 million and a median of -$6.8 million in 2022 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2025 — Free Cash Flow jumped 148.61% — and 2026, when it plunged 695.29%.
- Tracing DMRA's Free Cash Flow over 5 years: stood at -$11.5 million in 2022, then advanced by 11.91% to -$10.2 million in 2023, then soared by 70.95% to -$3.0 million in 2024, then jumped by 148.61% to $1.4 million in 2025, then sank by 1533.4% to -$20.6 million in 2026.
- The last three Free Cash Flow figures came in at -$20.6 million (Q1 2026), $1.4 million (Q4 2025), and -$2.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Damora Therapeutics | 1.92 Bn | 1.38 Bn | - | -21.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -21.90 Mn |
| Jun 30, 2026 | -21.90 Mn |
| Mar 31, 2026 | -20.60 Mn |
| Mar 31, 2026 | -20.60 Mn |
| Dec 31, 2025 | 1.44 Mn |
| Dec 31, 2025 | 1.44 Mn |
| Sep 30, 2025 | -2.92 Mn |
| Sep 30, 2025 | -2.92 Mn |
| Jun 30, 2025 | -2.46 Mn |
| Jun 30, 2025 | -2.46 Mn |
| Mar 31, 2025 | -2.59 Mn |
| Mar 31, 2025 | -2.59 Mn |
| Dec 31, 2024 | -2.96 Mn |
| Dec 31, 2024 | -2.96 Mn |
| Sep 30, 2024 | -3.82 Mn |
| Sep 30, 2024 | -3.82 Mn |
| Jun 30, 2024 | -4.38 Mn |
| Jun 30, 2024 | -4.38 Mn |
| Mar 31, 2024 | -6.48 Mn |
| Mar 31, 2024 | -6.48 Mn |